Eli Lilly investors are eager for Foundayo insight after early launch data

By Chris Prentice and Mariam Sunny

April 29 (Reuters) - Eli Lilly investors volition beryllium searching for thing they won't find successful immoderate first-quarter fiscal figures reported connected Thursday: penetration into the motorboat of weight-loss pill Foundayo.

U.S. income of the hotly anticipated obesity offering, a ‌rival to Novo Nordisk's Wegovy pill, began successful aboriginal April, truthful Foundayo information volition not beryllium included successful Lilly's first-quarter financials. Several much ‌weeks of medicine information is apt needed to find Foundayo's aboriginal income trajectory, 1 capitalist said.

But the pill volition inactive beryllium apical of mind, particularly with archetypal information prompting immoderate analysts to ​say Foundayo's motorboat is lagging Novo Nordisk's oral Wegovy, which deed the marketplace successful January.

"We’re 2 weeks into the launch, truthful it is truly excessively aboriginal successful my presumption to marque a factual telephone connected the spot of the launch," said BMO Capital Markets expert Evan Seigerman. "You're truly going to privation to perceive to however CEO Dave Ricks frames however the motorboat is going."

The archetypal information whitethorn not seizure direct-to-consumer sales, and investors typically request 5 to six weeks of information for ‌a due read, said Lilly capitalist Terence McManus of ⁠Bellevue Asset Management successful Zurich.

Lilly's stock terms has fallen 19% truthful acold this year, arsenic investors measurement the company's quality to conscionable lofty expectations for its obesity franchise that besides includes injected Zepbound successful the U.S. and Mounjaro, which is ⁠used for some diabetes and value nonaccomplishment extracurricular the U.S.

Strong planetary request for the Indianapolis-based drugmaker's diabetes and obesity medicines are expected to bolster a 26% emergence successful gross forecast by analysts, according to LSEG data.

Last year, Novo and Lilly began selling their obesity drugs successful India.

Sales of Lilly's Mounjaro doubled successful the months aft launch, making ​it ​the highest-selling cause successful the world's astir populous nation.

However, request is expected to look unit ​after Indian drugmakers started selling cheaper generic versions of Novo's ‌injectable Wegovy past month.

On Tuesday, Canada approved the archetypal generic mentation of Novo's Ozempic, an injectable diabetes medicine often utilized disconnected statement for value loss. Novo is owed to study quarterly results connected May 6.

INTERNATIONAL SALES IN FOCUS

Investors volition besides beryllium intimately eyeing the premix of pricing and request for the fashionable GLP-1 drugs some successful the U.S. and planetary markets.

"It's imaginable that implicit clip radical are underestimating the ex-U.S. component" for these products, Bellevue's McManus said.